Content Address Address Address Market         Description Address Add		DEPARTMENT OF HE FOOD AND D	CALTH AND HUMAN S RUG ADMINISTRATION	ERVICES	
Cincinnati, OH 45237-3097 (513) 679-2700 Fax: (513) 679-2772 Watchew J. Buderer , Vice President Matchev Breas Matchev Boservations and the phone number and address above. If you have an objection regarding an Seperifically, during aseptic production of human chorionic gonadotropin, DI (4) OBSERVATION 1 Aseptic processing areas are deficient regarding the system for monitoring environmental conditions. Specifically, Surface, viable air, non-viable air, and personnel monitoring for the ISO 5 area used to produce sterile drug products is not performed at least daily. OBSERVATION 3 Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product. Specifically, Matthew B Casale, Investigator Matchew B Casale, Investigator Matchew B Casale, Investigator Matchev B Casale, Investigator Matchev B Casale, Investigator Matchev B Casale, Investigator Matchev B Casale, Investigator					
(513) 679-2700 Fax: (513) 679-2772       3005664940         New control of Bodda, Development state       The state of the st				NUMBER	
Matthew J. Buderer, Vice President       anternational structure and the structure of			30	05664940	
Description         Preservations           Set of the structure of the structure interval	NAME AND TITLE OF INDIVIDUA	AL TO WHOM REPORT ISSUED		Craw a	
Buderer Drug Company Inc         26611 Dixie Hwy, Suite 119           Off MRL Brook Cooking         Producer of Strile Drug Products           Perrysburg, OH 43551-1765         Producer of Strile Drug Products           Prestysburg, OH 43551-1765         Producer of Strile Drug Products           Disadoument liss observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection achieves the phone number and address above.           DURING AN INSPECTION OF YOUR FIRM I OBSERVED:         OBSERVATION 1           Asseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.         Specifically, during aseptic production of human chorionic gonadotropin, 51(4)           OBSERVATION 2         Asseptic processing areas are deficient regarding the system for monitoring environmental conditions.           Specifically,         Specifically,           Surface, viable air, non-viable air, and personnel monitoring for the ISO 5 area used to produce sterile drug products is not performed at least daily.           OBSERVATION 3         Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.           Specifically,         Immoverse secure           Strengeneeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee		uderer , Vice President	X1144		
OWNE BALL         OWNE BALLE PROJECTION           Perrysburg, OH 43551-1765         Producer of Sterile Drug Products           This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection of your facility. They are inspection or yours and discuss the objection and observation, where an objection regarding an observation, you may discuss the objection of yours facility. They are inspection or yours and the objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection of yours facility. They are an objection regarding an observation, you may discuss the objection operation, and address above.           DURING AN INSPECTION OF YOUR FIRM I OBSERVED:           OBSERVATION 1           Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.           Specifically, during aseptic production of human chorionic gonadotropin, (b) (d)           OBSERVATION 2           Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.           Specifically,           Surface, viable air, non-viable air, and personnel monitoring for the ISO 5 area used to produce sterile drug products is not performed at least da			0.000000000000000000000000000000000000	11-112 M	
Perrysburg, OH 43551-1765       Producer of Sterile Drug Products         This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observation, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, you may discuss the objection action with the FDA representative(s) during the inspective action in response to an observation, you may discuss the objection action with the FDA representative(s) during the inspective action in response to an observation, you may discuss the objection action with the FDA representative(s) during the inspective action in response to an observation, you may discuss the objection action with the FDA representative(s) during the inspective action in response to an observation, you may discuss the objection action with the FDA representative(s) during the inspective action in response to an observation, you may discuss the objection action with the FDA representative(s) during the inspective action or submit this information to FDA at the address above. If you have an objection regarding an observation, you may discuss the objection action with the FDA representative(s) during the inspective action is proved at the address above. If you have an objection regarding an objection regarding an objection regarding at the submit this information to FDA at the address above. If you have an objective processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.         Specifically, during aseptic production of human chorionic gonadotropin, b) (4)       () (4)         OBSERVATION 2       Asseptic processing areas are deficient regarding the system for monitoring environmental conditions.         Specifically,					
observation, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, you may discuss the objection action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above. DURING AN INSPECTION OF YOUR FIRM I OBSERVED: OBSERVATION 1 A septic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure. Specifically, during aseptic production of human chorionic gonadotropin, (b) (d) of the ISO 5 compounding area and (b) (d) OBSERVATION 2 Aseptic processing areas are deficient regarding the system for monitoring environmental conditions. Specifically, Surface, viable air, non-viable air, and personnel monitoring for the ISO 5 area used to produce sterile drug products is not performed at least daily. OBSERVATION 3 Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product. Specifically,				74/4672.953.0	cts
OBSERVATION 1         Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.         Specifically, during aseptic production of human chorionic gonadotropin, (b) (4)         OBSERVATION 2         Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.         Specifically,         Surface, viable air, non-viable air, and personnel monitoring for the ISO 5 area used to produce sterile drug products is not performed at least daily.         OBSERVATION 3         Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.         Specifically,         Improvement and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.         Specifically,         Improvement Matthew B Casale, Investigator         Improvement Matthew B Casale, Investigator	observations, and do observation, or have action with the FDA	not represent a final Agency determination in implemented, or plan to implement, correcti representative(s) during the inspection or su	regarding your complia we action in response to bmit this information to	nce. If you have an objection reg o an observation, you may discuss	arding an s the objection (
particulate air filters under positive pressure. Specifically, during aseptic production of human chorionic gonadotropin, (2)(4) of the ISO 5 compounding area and (b)(4) OBSERVATION 2 Aseptic processing areas are deficient regarding the system for monitoring environmental conditions. Specifically, Surface, viable air, non-viable air, and personnel monitoring for the ISO 5 area used to produce sterile drug products is not performed at least daily. OBSERVATION 3 Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product. Specifically, Steffically,					
Specifically, during aseptic production of human chorionic gonadotropin, (2) (4)         of the ISO 5 compounding area and (2) (4)         OBSERVATION 2         Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.         Specifically,         Surface, viable air, non-viable air, and personnel monitoring for the ISO 5 area used to produce sterile drug products is not performed at least daily.         OBSERVATION 3         Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.         Specifically,         Improve the source sterile drug product.         OBSERVATION 3         Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.         Specifically,         Improve the Source of the ISO 5         Set REVERSE         OF THIS PAGE         Improve the B Casale, Investigator         Improve the source of the ISO 5	Aseptic process	ing areas are deficient regarding	air supply that is	filtered through high-effi	ciency
OBSERVATION 2         Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.         Specifically,         Surface, viable air, non-viable air, and personnel monitoring for the ISO 5 area used to produce sterile drug products is not performed at least daily.         OBSERVATION 3         Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.         Specifically,         Implement and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.         Specifically,         Implement and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.         Specifically,         Implement and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.         Specifically,         Implement and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety.         Implement and utensils are not maintained and sanitized at appropriate intervals to prevent conta			N7(07) 57	4	3525
OBSERVATION 2         Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.         Specifically,         Surface, viable air, non-viable air, and personnel monitoring for the ISO 5 area used to produce sterile drug products is not performed at least daily.         OBSERVATION 3         Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.         Specifically,         Implement and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.         Specifically,         Implement and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.         Specifically,         Implement and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.         Specifically,         Implement and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety.         Implement and utensils are not maintained and sanitized at appropriate intervals to prevent conta		NU NU NU NUMBER			
OBSERVATION 2         Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.         Specifically,         Surface, viable air, non-viable air, and personnel monitoring for the ISO 5 area used to produce sterile drug products is not performed at least daily.         OBSERVATION 3         Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.         Specifically,         Improvement and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.         Specifically,         Improvement and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.         Specifically,         Improvement and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.         Specifically,         Improvement and utensils are not maintained and sanitized at appropriate intervals to prevent contained and sanitized at appropriate intervals to prevent contained and sanitized at appropriate intervals to prevent contat approprise and to prevent contained approprise appr				otropin, <mark>(b) (4)</mark>	
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions. Specifically, Surface, viable air, non-viable air, and personnel monitoring for the ISO 5 area used to produce sterile drug products is not performed at least daily. OBSERVATION 3 Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product. Specifically, SEE REVERSE OF THIS PAGE Matthew B Casale, Investigator Matthew B Casale, Investigator Matthew B Casale, Investigator	of	the ISO 5 compounding area and	(b) (4)		
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions. Specifically, Surface, viable air, non-viable air, and personnel monitoring for the ISO 5 area used to produce sterile drug products is not performed at least daily. OBSERVATION 3 Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product. Specifically, SEE REVERSE OF THIS PAGE Matthew B Casale, Investigator Matthew B Casale, Investigator Matthew B Casale, Investigator					
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions. Specifically, Surface, viable air, non-viable air, and personnel monitoring for the ISO 5 area used to produce sterile drug products is not performed at least daily. OBSERVATION 3 Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product. Specifically, SEE REVERSE OF THIS PAGE Matthew B Casale, Investigator Matthew B Casale, Investigator Matthew B Casale, Investigator	ц.				at .
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions. Specifically, Surface, viable air, non-viable air, and personnel monitoring for the ISO 5 area used to produce sterile drug products is not performed at least daily. OBSERVATION 3 Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product. Specifically, SEE REVERSE OF THIS PAGE Matthew B Casale, Investigator Matthew B Casale, Investigator Matthew B Casale, Investigator					
Specifically, Surface, viable air, non-viable air, and personnel monitoring for the ISO 5 area used to produce sterile drug products is not performed at least daily.           OBSERVATION 3           Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product. Specifically,            See REVERSE OF THIS PAGE         EMPLOYEE(5) SIGNATURE Matthew B Casale, Investigator         Date ISSUED 1/4/2016	OBSERVATIO	ON 2		2 1	
Surface, viable air, non-viable air, and personnel monitoring for the ISO 5 area used to produce sterile drug products is not performed at least daily.           OBSERVATION 3           Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.           Specifically,           Image: See REVERSE OF THIS PAGE	Aseptic process	ing areas are deficient regarding	the system for mo	onitoring environmental of	conditions.
Surface, viable air, non-viable air, and personnel monitoring for the ISO 5 area used to produce sterile drug products is not performed at least daily.           OBSERVATION 3           Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.           Specifically,           Image: See REVERSE OF THIS PAGE					
drug products is not performed at least daily. OBSERVATION 3 Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product. Specifically, SEE REVERSE OF THIS PAGE Matthew B Casale, Investigator	Specifically,				
drug products is not performed at least daily. OBSERVATION 3 Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product. Specifically, SEE REVERSE OF THIS PAGE Matthew B Casale, Investigator	50 (50)				
drug products is not performed at least daily. OBSERVATION 3 Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product. Specifically, SEE REVERSE OF THIS PAGE Matthew B Casale, Investigator	Surface, viable	air non-viable air and nersonnel			
OBSERVATION 3         Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.         Specifically,         Image: Second colspan="2">Image: Second colspan="2" Image: Second colspan="2" Image		an, non-viable an, and bersonner	monitoring for th	ne ISO 5 area used to pro	duce sterile
Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product. Specifically,           Specifically,         Image: Content of the drug product of the drug product.           Specifically,         Image: Content of the drug product of the drug product.           See REVERSE OF THIS PAGE         Matthew B Casale, Investigator         Image: Content of the drug product of the drug product.	arug products is		monitoring for th	ne ISO 5 area used to pro	duce sterile
Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product. Specifically,           Specifically,         Image: Content of the drug product of the drug product.           Specifically,         Image: Content of the drug product of the drug product.           See REVERSE OF THIS PAGE         Matthew B Casale, Investigator         Image: Content of the drug product of the drug product.	arug products is		monitoring for th	ne ISO 5 area used to pro	duce sterile
Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product. Specifically,           Specifically,         Image: Content of the drug product of the drug product.           Specifically,         Image: Content of the drug product of the drug product.           See REVERSE OF THIS PAGE         Matthew B Casale, Investigator         Image: Content of the drug product of the drug product.	arug products is		monitoring for th	ne ISO 5 area used to pro	duce sterile
contamination that would alter the safety, identity, strength, quality or purity of the drug product. Specifically,           Specifically,           SEE REVERSE OF THIS PAGE           Matthew B Casale, Investigator           X Matthew B Casale, Spatter Bond	3	s not performed at least daily.	monitoring for th	ne ISO 5 area used to pro	duce sterile
Specifically,           SEE REVERSE OF THIS PAGE         EMPLOYEE(S) SIGNATURE Matthew B Casale, Investigator         Image: Compare to a sub- Matthew B Casale         DATE ISSUED 1/4/2016           Matthew B Casale, Investigator         X Matthew B Casale         DATE ISSUED 1/4/2016	OBSERVATIO	s not performed at least daily.			
SEE REVERSE OF THIS PAGE Matthew B Casale, Investigator X Matthew B Casale Note: Source Casale Note: Source Casale Note: Source Casale Note: Source Casale Note: Source Casale Note: Source Casale	OBSERVATIO Equipment and	s not performed at least daily. ON 3 utensils are not maintained and s	anitized at approp	priate intervals to preven	t
SEE REVERSE OF THIS PAGE Matthew B Casale, Investigator X Matthew B Casale Note: Source Casale Note: Source Casale Note: Source Casale Note: Source Casale Note: Source Casale Note: Source Casale	OBSERVATIO Equipment and	s not performed at least daily. ON 3 utensils are not maintained and s	anitized at approp	priate intervals to preven	t
SEE REVERSE OF THIS PAGE     EMPLOYEE(S) SIGNATURE Matthew B Casale, Investigator     Image: Comparison of the second sec	OBSERVATIO Equipment and contamination t	s not performed at least daily. ON 3 utensils are not maintained and s	anitized at approp	priate intervals to preven	t
SEE REVERSE OF THIS PAGE     EMPLOYEE(S) SIGNATURE Matthew B Casale, Investigator     Image: Comparison of the second sec	OBSERVATIO Equipment and contamination t	s not performed at least daily. ON 3 utensils are not maintained and s	anitized at approp	priate intervals to preven	t
SEE REVERSE OF THIS PAGE     EMPLOYEE(S) SIGNATURE Matthew B Casale, Investigator     Image: Comparison of the second sec	OBSERVATIO Equipment and contamination t	s not performed at least daily. ON 3 utensils are not maintained and s	anitized at approp	priate intervals to preven	t
SEE REVERSE OF THIS PAGE     EMPLOYEE(S) SIGNATURE Matthew B Casale, Investigator     Image: Comparison of the second sec	OBSERVATIO Equipment and contamination t	s not performed at least daily. ON 3 utensils are not maintained and s	anitized at approp	priate intervals to preven	t
SEE REVERSE OF THIS PAGE     Matthew B Casale, Investigator     I/4/2016       X Matthew B Casale     Noteen B Casale       Noteen B Casale     Signal by Matters B Casale	OBSERVATIO Equipment and contamination t	s not performed at least daily. ON 3 utensils are not maintained and s	anitized at approp	priate intervals to preven	t
SEE REVERSE OF THIS PAGE     Matthew B Casale, Investigator     I/4/2016       X Matthew B Casale     Noteen B Casale       Noteen B Casale     Signal by Matters B Casale	OBSERVATIO Equipment and contamination t	s not performed at least daily. ON 3 utensils are not maintained and s	anitized at approp	priate intervals to preven by or purity of the drug pr	t
OF THIS PAGE X Matthew B Casale Retrieve B Casal	OBSERVATIO Equipment and contamination t	s not performed at least daily. ON 3 utensils are not maintained and such at would alter the safety, identit	anitized at approp	priate intervals to preven by or purity of the drug pr	t oduct.
Rothers & Coskie Inschipfür Signal für Pethore & Coskie -5	OBSERVATIC Equipment and contamination t Specifically,	s not performed at least daily. ON 3 utensils are not maintained and such at would alter the safety, identit	anitized at approp y, strength, qualit	priate intervals to preven by or purity of the drug pr	t roduct.
	OBSERVATIO Equipment and contamination t Specifically, SEE REVERSE	s not performed at least daily. ON 3 utensils are not maintained and such at would alter the safety, identit	anitized at approp y, strength, qualit	oriate intervals to preven by or purity of the drug pr	t roduct.
	OBSERVATIO Equipment and contamination t Specifically, SEE REVERSE	s not performed at least daily. ON 3 utensils are not maintained and such at would alter the safety, identit	anitized at approp y, strength, qualit	Triate intervals to preven by or purity of the drug pr	t roduct.
	OBSERVATIO Equipment and contamination t Specifically, SEE REVERSE	s not performed at least daily. ON 3 utensils are not maintained and such at would alter the safety, identit	anitized at approp y, strength, qualit	Triate intervals to preven by or purity of the drug pr	t roduct.

		ND DRUG ADMINIST	UMAN SERVIC	ES	
DISTRICT ADDRESS AND PHON	NE NUMBER	IND DRUG ADMINIST	DATE(S) OF IN		
6751 Steger I				/2015-1/4/2016	5*
	OH 45237-3097 0 Fax:(513)679-2772		SO0566	54940	
Contractor and the second s					
Matthew T B	AL TO WHOM REPORT ISSUED uderer , Vice President				
FIRM NAME		STREET ADD	RESS		
Buderer Drug	Company Inc	26611	Dixie Hwy	7, Suite 119	
CITY, STATE, ZIP CODE, COUN	TRY OH 43551-1765	to be the second	JSHMENT INSPECTED	erile Drug Pro	a dura ba
There is no data products in the	a to support the storage of dep unclassified (0)(4) area for up t	byrogenated gla	assware use	d in the producti	ion of pa
	ON 4 ponents are not retested or ree age for long periods with sub-				
Specifically,	8 10				
1			nded for int	rathecal adminis	itration
OBSERVATIO Each batch of d determine confo	DN 5 Formance to such requirements	sterile and pyre		4 	
OBSERVATIO Each batch of d determine confo Specifically, Sterility and end	ON 5 rug product purporting to be	sterile and pyre	ogen-free is ch of sterile	not laboratory to	ested to
OBSERVATIO Each batch of d determine confo Specifically, Sterility and end including drug p	ON 5 rug product purporting to be sormance to such requirements dotoxin testing is not perform products intended for intrathe NSPECTION on),12/15/2015(Tue),12/16/20	sterile and pyres. ed on each bat	ogen-free is ch of sterile tion.	not laboratory to	ested to
OBSERVATIO Each batch of d determine confo Specifically, Sterility and end including drug p *DATES OF II 12/14/2015(Mo	ON 5 rug product purporting to be somance to such requirements dotoxin testing is not perform products intended for intrathe NSPECTION on),12/15/2015(Tue),12/16/20 Ion)	sterile and pyres. ed on each bat	ogen-free is ch of sterile tion.	not laboratory to	ested to roduced, n),12/29/2
OBSERVATIO Each batch of d determine confo Specifically, Sterility and end including drug p *DATES OF II 12/14/2015(Mo	ON 5 rug product purporting to be sormance to such requirements dotoxin testing is not perform products intended for intrathe NSPECTION on),12/15/2015(Tue),12/16/20	sterile and pyros. ed on each bat cal administra 15(Wed),12/1	ogen-free is ch of sterile tion.	not laboratory to	ested to